Platinums in lung cancer: Sufficient or necessary?

Journal of Clinical Oncology

Volumn 23, Issue 13, 2005, Pages 2882-2883

  Bunn Jr , Paul A ^a  

^a UNIVERSITY OF COLORADO CANCER CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CARBOPLATIN; CISPLATIN; DOCETAXEL; GEMCITABINE; NAVELBINE; PACLITAXEL; PLATINUM DERIVATIVE; RECOMBINANT GRANULOCYTE COLONY STIMULATING FACTOR; ANTINEOPLASTIC AGENT;

ANEMIA; BLOOD TOXICITY; CANCER STAGING; CLINICAL TRIAL; COMBINATION CHEMOTHERAPY; CONTROLLED CLINICAL TRIAL; DRUG EFFICACY; EDITORIAL; FEBRILE NEUTROPENIA; HUMAN; LUNG NON SMALL CELL CANCER; META ANALYSIS; MONOTHERAPY; NAUSEA AND VOMITING; NEPHROTOXICITY; NEUTROPENIA; PRACTICE GUIDELINE; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; SYSTEMATIC REVIEW; LUNG TUMOR; NOTE; PATHOLOGY;

ANTINEOPLASTIC AGENTS; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CARBOPLATIN; CARCINOMA, NON-SMALL-CELL LUNG; CISPLATIN; HUMANS; LUNG NEOPLASMS; META-ANALYSIS; RANDOMIZED CONTROLLED TRIALS;

EID: 19444372429     PISSN: 0732183X     EISSN: None     Source Type: Journal    
DOI: 10.1200/JCO.2005.11.930     Document Type: Editorial

References (17)

1. D'Addario G, Pintilie M, Leighl N, et al: Platinum-based versus non-platinum-based chemotherapy in advanced non-small-cell lung cancer: A meta-analysis of the published literature. J Clin Oncol 23:2926-2936, 2005
2. Georgoulias V, Ardavanis A, Tsiafaki X, et al: Vinorelbine plus cisplatin versus docetaxel plus gemcitabine in advanced non-small-cell lung cancer: A phase III randomized trial. J Clin Oncol 23:2937-2945, 2005
3. Pfister DG, Johnson DH, Azzoli CG, et al: American Society of Clinical Oncology: Treatment of unresectable non-small-cell lung cancer guideline: Update 2003. J Clin Oncol 22:330-353, 2004
4. Gralla RJ, Cvitkovic E, Golbey RB: Cis-Dichlorodiammineplatinum (II) in non-small cell carcinoma of the lung. Cancer Treat Rep 63:1585-1588, 1979
5. Bunn PA Jr, The expanding role of cisplatin in the treatment of non-small cell lung cancer. Semin Oncol 16:10-21, 1989 (4 suppl 6)
6. Non-small Cell Lung Cancer Collaborative Group: Chemotherapy in non-small cell lung cancer: A meta-analysis using updated data on individual patients from 52 randomized clinical trials. BMJ 311:899-909, 1995
7. American Society of Clinical Oncology: Clinical practice guidelines for the treatment of unresectable non-small-cell lung cancer. J Clin Oncol 15:2996-3018, 1997
8. Bunn PA Jr, Kelly K: New chemotherapeutic agents prolong survival and improve quality of life in non-small cell lung cancer: A review of the literature and future directions. Clin Cancer Res 4:1087-1100, 1998
9. Ranson M, Davidson N, Nicolson M, et al: Randomized trial of paclitaxel plus supportive care versus supportive care for patients with advanced non-small cell lung cancer. J Natl Cancer Inst 92:1074-1080, 2000
10. Roszkowski K, Pluzanska A, Krazakowski M, et al: A multicenter, randomized phase III study of docetaxel plus best supportive care versus best supportive care in chemotherapy-naïve patients with metastatic or non-resectable localized non-small cell lung cancer (NSCLC). Lung Cancer 27:145-157, 2000
11. Sandler AB, Nemunaitis J, Denham C, et al: Phase II trial of gemcitabine plus cisplatin versus cisplatin alone in patients with locally advanced or metastatic non-small-cell lung cancer. J Clin Oncol 18:122-130, 2000
12. Wozniak AJ, Crowley JJ, Balcerzak SP, et al: Randomized trial comparing cisplatin with cisplatin plus vinorelbine in the treatment of advanced non-small cell lung cancer: A Southwest Oncology Group study. J Clin Oncol 16:2459-2465, 1998
13. Le Chevalier T, Brisgand D, Douillard JY, et al: Randomized study of vinorelbine and cisplatin versus vindesine and cisplatin versus vinorelbine alone in advanced non-small-cell lung cancer: Results of a European multicenter trial including 612 patients. J Clin Oncol 12:360-367, 1994
14. Lilenbaum RC, Herndon J, List M, et al: Single agent (SA) versus combination chemotherapy (CC) in advanced non-small cell lung cancer (NSCLC): A CALGB randomized trial of efficacy, quality of life (QOL), and cost-effectiveness. Proc Am Soc Clin Oncol 21:1, 2002 (abstr 2)
15. Sederholm C: Gemcitabine (G) compared with gemcitabine plus carboplatin (GC) in advanced non-small cell lung cancer (NSCLC): A phase III study by the Swedish Lung Cancer Study Group (SLCSG). Proc Am Soc Clin Oncol 21:291a, 2002 (abstr 1162)
16. Georgoulias V, Ardavanis A, Agellidou M, et al: Preliminary analysis of a multicenter phase III trial comparing docetaxel (D) versus docetaxel/cisplatin (DC) in patients with inoperable advanced and metastatic non-small cell lung cancer (NSCLC). Proc Am Soc Clin Oncol 21:291a, 2002 (abstr 1163)
17. Bunn PA Jr: Chemotherapy for advanced non-small cell lung cancer: Who, What, When, Why? J Clin Oncol 20:23s-33s, 2002 (suppl 18)